---
title: CAR T-cell Therapy Landscape in Pediatric, Adolescent and Young Adult Oncology
  - A Comprehensive Analysis of Clinical Trials
date: '2025-02-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39900318/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250204170846&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a transformative
  approach in cancer treatment, particularly for hematologic malignancies. This therapy
  involves the genetic modification of patients' T-cells to target specific tumor
  antigens, bypassing the traditional MHC-TCR-mediated recognition. This innovation
  marks a significant step toward personalized medicine and precision oncology. In
  the pediatric, adolescent, and young adult (P-AYA) populations, Tisagenlecleucel
  ...
disable_comments: true
---
Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a transformative approach in cancer treatment, particularly for hematologic malignancies. This therapy involves the genetic modification of patients' T-cells to target specific tumor antigens, bypassing the traditional MHC-TCR-mediated recognition. This innovation marks a significant step toward personalized medicine and precision oncology. In the pediatric, adolescent, and young adult (P-AYA) populations, Tisagenlecleucel ...